p53 antibody testing is covered by insurance for three cancers: esophageal cancer, colon cancer, and breast cancer. It is an IgG autoantibody induced in serum against p53 protein mutations caused by p53 gene abnormalities in cancer cells and can be detected even in relatively early stages of cancer. The clinical feature is that it is not affected by age, gender, inflammation, or smoking history. It is useful for early diagnostic aids and post-treatment monitoring.
